Small molecules targeting severe acute respiratory syndrome human coronavirus
- 28 June 2004
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 101 (27), 10012-10017
- https://doi.org/10.1073/pnas.0403596101
Abstract
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a novel human coronavirus. Currently, no effective antiviral agents exist against this type of virus. A cell-based assay, with SARS virus and Vero E6 cells, was developed to screen existing drugs, natural products, and synthetic compounds to identify effective anti-SARS agents. Of >10,000 agents tested, ≈50 compounds were found active at 10 μM; among these compounds, two are existing drugs (Reserpine 13 and Aescin 5) and several are in clinical development. These 50 active compounds were tested again, and compounds 2–6, 10, and 13 showed active at 3 μM. The 50% inhibitory concentrations for the inhibition of viral replication (EC50) and host growth (CC50) were then measured and the selectivity index (SI = CC50/EC50) was determined. The EC50, based on ELISA, and SI for Reserpine, Aescim, and Valinomycin are 3.4 μM (SI = 7.3), 6.0 μM (SI = 2.5), and 0.85 μM (SI = 80), respectively. Additional studies were carried out to further understand the mode of action of some active compounds, including ELISA, Western blot analysis, immunofluorescence and flow cytometry assays, and inhibition against the 3CL protease and viral entry. Of particular interest are the two anti-HIV agents, one as an entry blocker and the other as a 3CL protease inhibitor (K i = 0.6 μM).Keywords
This publication has 47 references indexed in Scilit:
- Characterization of SARS main protease and inhibitor assay using a fluorogenic substrateBiochemical and Biophysical Research Communications, 2004
- Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CLproBiochemistry, 2004
- Vitamin C and SARS coronavirusJournal of Antimicrobial Chemotherapy, 2003
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Urgent search for safe and effective treatments of severe acute respiratory syndrome: is melatonin a promising candidate drug?Journal of Pineal Research, 2003
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- The Genome Sequence of the SARS-Associated CoronavirusScience, 2003
- Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 2003
- Aescin: pharmacology, pharmacokinetics and therapeutic profilePharmacological Research, 2001
- MTS Interferon Assay: A Simplified Cellular Dehydrogenase Assay for Interferon Activity Using a Water-Soluble Tetrazolium SaltJournal of Interferon & Cytokine Research, 1996